You just read:

ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

News provided by

ThromboGenics

10 Jan, 2017, 01:30 ET